Journal article

Accelerated Gray and White Matter Deterioration With Age in Schizophrenia

Vanessa L Cropley, Paul Klauser, Rhoshel K Lenroot, Jason Bruggemann, Suresh Sundram, Chad Bousman, Avril Pereira, Maria A Di Biase, Thomas W Weickert, Cynthia Shannon Weickert, Christos Pantelis, Andrew Zalesky

American Journal of Psychiatry | AMER PSYCHIATRIC PUBLISHING, INC | Published : 2017

Grants

Awarded by National Health and Medical Research Council (NHMRC) Early Career Fellowship


Awarded by Brain and Behavior Research Foundation (NARSAD) Young Investigator Award


Awarded by Swiss Society for Medicine and Biology Scholarships


Awarded by NHMRC Senior Principal Research Fellowship


Awarded by NHMRC Senior Research Fellowship


Awarded by NHMRC Fellowship


Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

Dr. Cropley was supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (628880), a Brain and Behavior Research Foundation (NARSAD) Young Investigator Award (21660), and a University of Melbourne Faculty of Medicine, Dentistry, and Health Sciences Research Fellowship. Dr. Klauser was supported by the Swiss National Science Foundation (SNSF), by the Swiss Society for Medicine and Biology Scholarships (148384), and by the National Center for Competence in Research (SYNAPSY), founded by SNSF. Dr. Bousman was supported by a University of Melbourne Ronald Phillip Griffith Fellowship and by a Brain and Behavior Research Foundation (NARSAD) Young Investigator Award (20526). Dr. Pereira was supported by the One-in-Five Association and the AMP Foundation. Ms. Di Biase was supported by an Australian Rotary Health, Ian Scott, Ph.D., Scholarship in Mental Health. Dr. Pantelis was supported by an NHMRC Senior Principal Research Fellowship (628386 and 1105825) and by a Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Award. Dr. Cynthia Shannon Weickert was supported by an NHMRC Senior Research Fellowship (1021970), the Schizophrenia Research Institute (using infrastructure from the New South Wales Ministry of Health and the Macquarie Group Foundation), the University of New South Wales, and Neuroscience Research Australia. Dr. Zalesky was supported by an NHMRC Fellowship (1047648).Data for this study were provided by the Australian Schizophrenia Research Bank (ASRB), which is supported by the National Health and Medical Research Council of Australia (enabling grant 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. The authors thank the chief investigators and manager of the ASRB: Carr V, Schall U, Scott R, Jablensky A, Mowry B, Michie P, Catts S, Henskens F, Pantelis C, and Loughland C. The authors acknowledge the help of Jason Bridge for ASRB database queries.Dr. Sundram has received consulting fees, advisory board fees, research support, speakers honoraria, or travel support from AstraZeneca, the Australian National Health and Medical Research Council, the Australian Department of Immigration and Border Protection, Bristol-Myers Squibb, Eli Lilly, the Flack Trust, GlaxoSmithKline, Lundbeck, the One-in-Five Association, Otsuka, Pfizer, Roche, and the United Nations High Commissioner for Refugees. Dr. Cynthia Shannon Weickert is on an advisory board for and has received advisory board fees from Lundbeck. Over the last 4 years, Dr. Pantelis has been on advisory boards for AstraZeneca, Janssen-Cilag, Lundbeck, and Servier; and he has received honoraria for talks presented at educational meetings organized by AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, and Shire. The other authors report no financial relationships with commercial interests.